via ft.com
Some of the biggest investors in AstraZeneca are calling for a radical shake-up of the board and executive team, as a new chairman prepares to join the underperforming Anglo-Swedish pharmaceutical group.
With the company trading on the lowest price/earnings multiple in the sector, some large shareholders have been lobbying to replace David Brennan as chief executive and push for a fresh business strategy.
No comments:
Post a Comment